Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Claudin-1, A Double-Edged Sword in Cancer.

Bhat AA, Syed N, Therachiyil L, Nisar S, Hashem S, Macha MA, Yadav SK, Krishnankutty R, Muralitharan S, Al-Naemi H, Bagga P, Reddy R, Dhawan P, Akobeng A, Uddin S, Frenneaux MP, El-Rifai W, Haris M.

Int J Mol Sci. 2020 Jan 15;21(2). pii: E569. doi: 10.3390/ijms21020569. Review.

2.

Exploring Dysregulated Signaling Pathways in Cancer.

Nisar S, Hashem S, Macha MA, Yadav SK, Muralitharan S, Azeez L, Sageena G, Al-Naemi H, Haris M, Bhat AA.

Curr Pharm Des. 2020 Jan 14. doi: 10.2174/1381612826666200115095937. [Epub ahead of print]

PMID:
31939726
3.

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.

Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N.

J Exp Clin Cancer Res. 2019 Jun 18;38(1):266. doi: 10.1186/s13046-019-1264-2.

4.

Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.

Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, Grandgenett PM, Kaur S, Batra SK.

EBioMedicine. 2019 Apr;42:375-385. doi: 10.1016/j.ebiom.2019.03.056. Epub 2019 Apr 5.

5.

Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.

Chaudhary S, Ganguly K, Muniyan S, Pothuraju R, Sayed Z, Jones DT, Batra SK, Macha MA.

J Natl Cancer Inst. 2019 Mar 1;111(3):233-244. doi: 10.1093/jnci/djy207.

6.

Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells.

Vengoji R, Ponnusamy MP, Rachagani S, Mahapatra S, Batra SK, Shonka N, Macha MA.

Carcinogenesis. 2019 Mar 12;40(1):2-14. doi: 10.1093/carcin/bgy171. Review.

PMID:
30475990
7.

Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.

Jahan R, Macha MA, Rachagani S, Das S, Smith LM, Kaur S, Batra SK.

Biochim Biophys Acta Mol Basis Dis. 2018 Aug;1864(8):2538-2549. doi: 10.1016/j.bbadis.2018.05.008. Epub 2018 May 16.

8.

Natural products: a hope for glioblastoma patients.

Vengoji R, Macha MA, Batra SK, Shonka NA.

Oncotarget. 2018 Apr 24;9(31):22194-22219. doi: 10.18632/oncotarget.25175. eCollection 2018 Apr 24. Review.

9.

Emerging therapeutic potential of graviola and its constituents in cancers.

Qazi AK, Siddiqui JA, Jahan R, Chaudhary S, Walker LA, Sayed Z, Jones DT, Batra SK, Macha MA.

Carcinogenesis. 2018 Apr 5;39(4):522-533. doi: 10.1093/carcin/bgy024. Review.

10.

Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.

Macha MA, Rachagani S, Qazi AK, Jahan R, Gupta S, Patel A, Seshacharyulu P, Lin C, Li S, Wang S, Verma V, Kishida S, Kishida M, Nakamura N, Kibe T, Lydiatt WM, Smith RB, Ganti AK, Jones DT, Batra SK, Jain M.

Oncotarget. 2017 Mar 28;8(13):20961-20973. doi: 10.18632/oncotarget.15468.

11.

MUC4 is negatively regulated through the Wnt/β-catenin pathway via the Notch effector Hath1 in colorectal cancer.

Pai P, Rachagani S, Dhawan P, Sheinin YM, Macha MA, Qazi AK, Chugh S, Ponnusamy MP, Mallya K, Pothuraju R, Batra SK.

Genes Cancer. 2016 May;7(5-6):154-168. doi: 10.18632/genesandcancer.108.

12.

The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.

Pai P, Rachagani S, Lakshmanan I, Macha MA, Sheinin Y, Smith LM, Ponnusamy MP, Batra SK.

Mol Oncol. 2016 Feb;10(2):224-39. doi: 10.1016/j.molonc.2015.10.005. Epub 2015 Oct 19.

13.

Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.

Rachagani S, Macha MA, Menning MS, Dey P, Pai P, Smith LM, Mo YY, Batra SK.

Oncotarget. 2015 Nov 24;6(37):40295-309. doi: 10.18632/oncotarget.5641.

14.

Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Macha MA, Krishn SR, Jahan R, Banerjee K, Batra SK, Jain M.

Cancer Treat Rev. 2015 Mar;41(3):277-88. doi: 10.1016/j.ctrv.2015.01.001. Epub 2015 Jan 14. Review.

15.

Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Rachagani S, Macha MA, Heimann N, Seshacharyulu P, Haridas D, Chugh S, Batra SK.

Adv Drug Deliv Rev. 2015 Jan;81:16-33. doi: 10.1016/j.addr.2014.10.020. Epub 2014 Oct 23. Review.

16.

Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications.

Lakshmanan I, Ponnusamy MP, Macha MA, Haridas D, Majhi PD, Kaur S, Jain M, Batra SK, Ganti AK.

J Thorac Oncol. 2015 Jan;10(1):19-27. doi: 10.1097/JTO.0000000000000404. Review.

17.

Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma.

Kamikawa Y, Kanmura Y, Hamada T, Yamada N, Macha MA, Batra SK, Higashi M, Yonezawa S, Sugihara K.

Int J Clin Oncol. 2015 Apr;20(2):298-307. doi: 10.1007/s10147-014-0710-6. Epub 2014 Jun 10.

PMID:
24909613
18.

MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers.

Macha MA, Seshacharyulu P, Krishn SR, Pai P, Rachagani S, Jain M, Batra SK.

Curr Pharm Des. 2014;20(33):5287-97. Review.

19.

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.

Macha MA, Batra SK, Ganti AK.

Cancer Manag Res. 2013 Jul 31;5:197-203. doi: 10.2147/CMAR.S45976. Print 2013.

20.

Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling.

Macha MA, Rachagani S, Gupta S, Pai P, Ponnusamy MP, Batra SK, Jain M.

Cancer Lett. 2013 Dec 1;341(2):166-77. doi: 10.1016/j.canlet.2013.07.037. Epub 2013 Aug 3.

Supplemental Content

Loading ...
Support Center